Allo-hNHL (FluBuCy)
Launched by INSTITUT FUER ANWENDUNGSORIENTIERTE FORSCHUNG UND KLINISCHE STUDIEN GMBH · Nov 4, 2008
Trial Information
Current as of May 22, 2025
Completed
Keywords
ClinConnect Summary
Patients in the age of 18 to 65 years with a high- risk relapse of a histology proven aggressive Non-Hodgkin's-lymphoma are eligible for the trial. Aggressive Non-Hodgkin's lymphoma within this study is defined as:
B-NHL:
follicular lymphoma grade III° lymphoblastic (precursor) lymphoma diffuse large cell cell lymphoma any subtype and variant including primary mediastinal lymphoma mantle cell lymphoma, blastic variant
T-NHL:
precursor T cell lymphoma peripheral T cell lymphoma, any subtype and variant angioimmunoblastic lymphoma anaplastic large cell lymphoma, any subtype NK / T cell ly...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • histology proven aggressive non Hodgkin's lymphoma and
- • primary progressive disease or
- • early relapse after less than 12 month of remission duration and at least one risk factor according to the international prognostic index (IPI or
- • relapse or progression after high dose chemotherapy and autologous transplantation or
- • relapse or progression and lack of an autologous stem cell product.
- Exclusion Criteria:
- • severe comorbidity or impaired organ function
- • hypersensitivity to used drugs
- • HIV positivity
- • active hepatitis
- • other active malignant disease
About Institut Fuer Anwendungsorientierte Forschung Und Klinische Studien Gmbh
Institut für Anwendungsorientierte Forschung und Klinische Studien GmbH is a leading research organization dedicated to advancing clinical research and applied science. With a strong focus on innovative methodologies and robust study designs, the institute collaborates with various stakeholders in the healthcare sector to facilitate the development and evaluation of new therapeutic interventions. By leveraging a multidisciplinary team of experts, the organization aims to enhance patient outcomes through rigorous clinical trials that adhere to the highest ethical and regulatory standards. Its commitment to excellence and scientific integrity positions it as a trusted partner in the clinical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hamburg, , Germany
Heidelberg, Baden Würtenberg, Germany
Marburg, Hessen, Germany
Homburg, Saarland, Germany
Göttingen, , Germany
Münster, , Germany
Patients applied
Trial Officials
Bertram Glass, Prof. MD.
Study Director
Asklepios Klinik St. Georg
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials